EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Delineation of monocytic and early‐stage myeloid‐derived suppressor cells in the peripheral blood of patients with hepatocarcinoma

Marta Chivite-Lacaba iD, Iago Justo, Alberto Utrero-Rico iD, Oscar Caso, Cecilia González-Cuadrado iD, Manuel J Del Rey, Rocio Laguna-Goya iD, Javier Arroyo-Ródenas, Ángel Alfocea-Molina, Carlota C Ruigómez-Martín, Manuel Serrano, Lorena Pascual-Palacios und 2 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Marta Chivite-Lacaba und 13 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Myeloid-Derived Suppressor Cells, Liver Neoplasms, Monocytes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Private Proyect, Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with hepatocellular carcinoma (HCC), increased myeloid‐derived suppressor cells (MDSC) relate to aggressiveness and poor prognosis. Favorable responses with immune checkpoint inhibitors demonstrate that HCC is susceptible to immune activation, suggesting that the elimination of MDSC would provide therapeutic benefits. However, a global analysis of the different MDSC subsets in HCC is still missing. Here we phenotyped circulating myeloid cell subsets (monocytes, M‐MDSC, PMN‐MDSC and eMDSC) by flow cytometry in HCC and hepatocholangiocarcinoma patients and in healthy donors (HD). Isolated myeloid CD33 + cells were analyzed in immunosuppression assays, and cytokines were quantified in the supernatants. Arginase‐1 activity (Arg‐1) was analyzed in serum samples. All three proportions of MDSC, together with the immunosuppressive Arg‐1, were significantly increased in HCC compared with HD. An important proportion of eMDSC expressed CD25, the IL‐2 receptor α chain, and CD25 + eMDSC were also significantly expanded in HCC patients. HCC‐CD33 + cells, enriched in M‐MDSC and eMDSC, in vitro inhibited both CD4 + and CD8 + T cell proliferation and IL‐2 production, and augmented IL‐10, IL‐6, and TNF‐α. The correlation between the inhibition of T lymphocyte proliferation and M‐MDSC was the strongest, while eMDSC or CD25 + eMDSC did not show antiproliferative capacity. Despite this functional difference, M‐MDSC, CD25 + eMDSC, and CD25 expression in eMDSC were more prominent in advanced HCC as defined by a higher number of nodules, TNM stage, and alpha‐fetoprotein level. This better delineation of M‐MDSC and eMDSC phenotype and function in HCC could help to design therapies more likely to succeed in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularMyeloid-Derived Suppressor CellsLiver NeoplasmsMonocytesHumansMaleFemaleMiddle AgedArginaseAgedCytokinesAdultSialic Acid Binding Ig-like Lectin 3Interleukin-2 Receptor alpha SubunitCell Proliferation

Stichwörter der Autor:innen

MDSChepatocarcinomaimmunosuppressionmyeloid derived suppressor cells

Substanzen

ArginaseARG1 protein, humanCytokinesSialic Acid Binding Ig-like Lectin 3Interleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Department of Surgery and Abdominal Organs Transplantation, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Immunology, Ophthalmology and Nose and Throat (ENT), Medical School, Universidad Complutense de Madrid, Madrid, Spain.

ORCID-Profile: Marta Chivite-Lacaba, Alberto Utrero-Rico, Cecilia González-Cuadrado, Rocio Laguna-Goya, María Esther Mancebo, Estela Paz-Artal

Förderung

  • Private Proyect
  • Fundación Científica Asociación Española Contra el Cáncer
  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III

Zitieren

APA

Chivite-Lacaba, M., Justo, I., Utrero-Rico, A., Caso, O., González-Cuadrado, C., Del Rey, M. J., Laguna-Goya, R., Arroyo-Ródenas, J., Alfocea-Molina, Á., Ruigómez-Martín, C. C., Serrano, M., Pascual-Palacios, L., Mancebo, M. E., & Paz-Artal, E. (2025). Delineation of monocytic and early‐stage myeloid‐derived suppressor cells in the peripheral blood of patients with hepatocarcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.35390

Vancouver

Chivite-Lacaba M, Justo I, Utrero-Rico A, Caso O, González-Cuadrado C, Del Rey MJ, et al. Delineation of monocytic and early‐stage myeloid‐derived suppressor cells in the peripheral blood of patients with hepatocarcinoma. International Journal of Cancer. 2025. doi:10.1002/ijc.35390

BibTeX
@article{ChiviteLacaba2025,
  author = {Chivite-Lacaba, Marta and Justo, Iago and Utrero-Rico, Alberto and Caso, Oscar and González-Cuadrado, Cecilia and Del Rey, Manuel J and Laguna-Goya, Rocio and Arroyo-Ródenas, Javier and Alfocea-Molina, Ángel and Ruigómez-Martín, Carlota C and Serrano, Manuel and Pascual-Palacios, Lorena and Mancebo, María Esther and Paz-Artal, Estela},
  title = {Delineation of monocytic and early‐stage myeloid‐derived suppressor cells in the peripheral blood of patients with hepatocarcinoma},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35390}
}
Kostenlos starten →